Evaluating HER2 amplification and overexpression in breast cancer

Journal of Pathology

Volumn 195, Issue 4, 2001, Pages 422-428

  Bartlett, John M S ^a   Going, James J ^a   Mallon, Elizabeth A ^b   Watters, Amanda D ^a   Reeves, Jonathan R ^a   Stanton, Peter ^a   Richmond, Jim ^a   Donald, Brian ^a   Ferrier, Rhona ^b   Cooke, Timothy G ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; c erB2; FISH; Herceptin; Immunohistochemistry accuracy; Trazumatab

Indexed keywords

FORMALDEHYDE; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; ASSAY; BREAST CANCER; BREAST CARCINOMA; CONTROLLED STUDY; DEVICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; OBSERVER VARIATION; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; TISSUE FIXATION;

ANTIBODIES, MONOCLONAL; AUTORADIOGRAPHY; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; CONFIDENCE INTERVALS; FEMALE; FROZEN SECTIONS; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIFE TABLES; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; TRANS-ACTIVATION (GENETICS);

EID: 0035162262     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.971     Document Type: Article

References (43)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder
3. C-erbB2 oncogene expression in ovarian cancers
4. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines
5. Amplification of HER-2/neu gene in human gastric adenocarcinomas: Correlation with primary site
6. C-erbB2 amplification as a molecular marker in bladder cancer
7. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
8. ERBB2 oncogene in human breast cancer and its clinical significance
9. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
10. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
11. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: Comparison with c-erbB-2 gene amplification
12. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
13. Oncogene amplification and expression. Importance of methodologic considerations
14. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
15. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer
16. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
17. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
18. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis
19. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
20. Lack of interaction of tamoxifen use and erbB2/Her2/neu expression in CALGB 8541: A randomised adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil in node positive primary breast cancer
21. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
22. Initial report of the SWOG biological correlative study of c-erbB2 expression as a predictor of outcome in a trial comparing adjuvant CAF-T with tamoxifen (T) alone
23. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
24. Localization of EGF receptors in frozen tissue sections by antibody and biotinylated EGF-based techniques
25. Quantitative radioimmunohistochemical measurements of p185 (erbB-2) in frozen tissue sections
26. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer
27. Human squamous cell lung cancers express increased epidermal growth factor receptors
28. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival
29. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
30. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
31. Markers of tumour burden: An overview
32. Estrogen receptors in 699 primary breast cancers: A comparison of immunohistochemical and biochemical methods
33. Overview of the Trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
34. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer
35. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry
36. A scoring system for immunohistochemical staining: Consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group
37. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?
38. Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy
39. Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder
40. Recommendations for Her2 testing in the UK
41. Her2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridisation
42. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study